Payment overview · 2025
General Payments
$48.75
2 reported records · 2 companies
Healthcare provider profile · identity verified
David Emory Lippman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EVANSVILLE, IN · NPI 1922090349
Verified facts
What the public records show
CMS Open Payments records show David Emory Lippman, M.D. received $48.75 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 66.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.27 | 66.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.48 | 33.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $32.27 | 1 |
| Food and Beverage | $16.48 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 707 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 518 | 140 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 342 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 77 |
| Gabapentin | Gabapentin | 323 | 85 |
| Losartan Potassium | Losartan Potassium | 298 | 72 |
| Lisinopril | Lisinopril | 288 | 69 |
| Omeprazole | Omeprazole | 244 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 231 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 57 |
| Furosemide | Furosemide | 195 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 49 |
| Famotidine | Famotidine | 170 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 41 |
| Potassium Chloride | Potassium Chloride | 158 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 40 |
| Farxiga | Dapagliflozin Propanediol | 150 | 34 |
| Metformin Hcl | Metformin Hcl | 144 | 36 |
| Trazodone Hcl | Trazodone Hcl | 143 | 41 |
| Metformin Hcl Er | Metformin Hcl | 141 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 33 |
| Carvedilol | Carvedilol | 113 | 30 |
| Ozempic | Semaglutide | 112 | 28 |
| Buspirone Hcl | Buspirone Hcl | 108 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 36 |
| Glimepiride | Glimepiride | 93 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 32 |
| Allopurinol | Allopurinol | 90 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 21 |
| Clotrimazole | Clotrimazole | 77 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 25 |
| Lovastatin | Lovastatin | 72 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 71 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 19 |
| Montelukast Sodium | Montelukast Sodium | 69 | 20 |
| Meclizine Hcl | Meclizine Hcl | 66 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 29 |
| Clonidine Hcl | Clonidine Hcl | 60 | 21 |
| Jardiance | Empagliflozin | 60 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 18 |
| Baclofen | Baclofen | 57 | 20 |
| Atenolol | Atenolol | 56 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 19 |
| Sertraline Hcl | Sertraline Hcl | 54 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 18 |
| Pregabalin | Pregabalin | 52 | 19 |
| Ketoconazole | Ketoconazole | 51 | 17 |
| Tradjenta | Linagliptin | 51 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 50 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Ezetimibe | Ezetimibe | 46 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Eliquis | Apixaban | 45 | 12 |
| Myrbetriq | Mirabegron | 45 | 11 |
| Enalapril Maleate | Enalapril Maleate | 44 | 11 |
| Promethazine Hcl | Promethazine Hcl | 43 | 19 |
| Spironolactone | Spironolactone | 43 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 12 |
| Ondansetron Odt | Ondansetron | 40 | 14 |
| Simvastatin | Simvastatin | 40 | 11 |
| Lidocaine | Lidocaine | 39 | 18 |
| Nitroglycerin | Nitroglycerin | 38 | 21 |
| Ramipril | Ramipril | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 33 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | 16 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | 13 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 11 |
| Risperidone | Risperidone | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 24 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 14 |
| Nystatin | Nystatin | 29 | 12 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 23 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 23 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Valsartan | Valsartan | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 12 |
| Colchicine | Colchicine | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $48.75 · 2 records | Novo Nordisk Inc | ELIQUIS, NURTEC ODT, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error